Nisa Investment Advisors’s The Oncology Institute TOI Stock Holding History

Nisa Investment Advisors’s Portfolio TOI Stock Details TOI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	–	–	2708
2022 Q4	$0	Buy	+13	New	+$36	﹤0.01%	2728

Other funds holding TOI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Nisa Investment Advisors's TOI Position: Q1 2023 in Review

Nisa Investment Advisors sold out of The Oncology Institute (TOI) in Q1 2023, closing a stake of 13 shares.

Nisa Investment Advisors first reported a position in TOI in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 39 funds tracked by Wall St. Rank hold TOI as of Q1 2023.

Nisa Investment Advisors reported no remaining The Oncology Institute position as of Q1 2023 after selling out during the quarter.
Nisa Investment Advisors sold 13 The Oncology Institute shares in Q1 2023.
Nisa Investment Advisors first reported a position in The Oncology Institute in Q4 2022 and held it in 1 quarter.
Nisa Investment Advisors's The Oncology Institute position peaked at $0 in Q4 2022.
39 funds tracked by Wall St. Rank held The Oncology Institute as of Q1 2023.

Based on Nisa Investment Advisors's 13F filing for Q1 2023, filed 2 May 2023.